Ventures Ix, L.P.Battery In... Net Worth

The estimated Net Worth of Ventures Ix, L.P.Battery In... is at least $90.7 Milhão dollars as of 11 March 2015. Ventures In owns over 6,250,000 units of Champions Oncology Inc stock worth over $90,683,833 and over the last 12 years Ventures sold CSBR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures In CSBR stock SEC Form 4 insiders trading

Ventures has made over 2 trades of the Champions Oncology Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ventures bought 6,250,000 units of CSBR stock worth $2,500,000 on 11 March 2015.

The largest trade Ventures's ever made was buying 7,000,000 units of Champions Oncology Inc stock on 28 January 2013 worth over $3,500,000. On average, Ventures trades about 6,625,000 units every 386 days since 2013. As of 11 March 2015 Ventures still owns at least 22,281,040 units of Champions Oncology Inc stock.

You can see the complete history of Ventures In stock trades at the bottom of the page.

Insiders trading at Champions Oncology Inc

Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, eSports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.

What does Champions Oncology Inc do?

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them

Complete history of Ventures In stock trades at Champions Oncology Inc

Champions Oncology Inc executives and stock owners

Champions Oncology Inc executives and other stock owners filed with the SEC include:

• Ronnie Morris,
  Chief Executive Officer, Director
• Dr. Ronnie Morris M.D.,
  Pres, CEO & Director
• David Miller,
  Chief Financial Officer
• David Barry Miller M.B.A.,
  Chief Financial Officer
• Joel Ackerman,
  Chairman of the Board
• Scott Tobin,
  Independent Director
• Abba Poliakoff,
  Independent Director
• Daniel Mendelson,
  Independent Director
• David Sidransky,
  Lead Independent Director
• Philip Breitfeld,
  Independent Director
• David DeOrnellis BS, CMAR, CPIA, RLATG,
  Exec. VP of Global Laboratory Operations
• Dr. Maria Mancini Ph.D.,
  Chief of Scientific Operations
• Dr. Michael Ritchie M.B.A., Ph.D.,
  Chief Commercial Officer
• Dr. Karin Abarca Heidemann,
  VP of Scientific Operations
• Ventures Ix, L.P.Battery In...,
  
• Michael Maurice Feldman Jes...,
  
• Ventures Ix, L.P.Battery In...,
  
• Arthur G Iii Epker,
  Director
• Michael Maurice Brown,
  10% owner
• James Martell,
  Chief Accounting Officer
• Ana Stancic,
  Director
• Douglas D Burkett,
  President
• Mark Schonau,
  Chief Financial Officer
• Durwood Settles,
  Director
• Sports Inc Champions,
  Chairman, President
• Enterprise Associates 14, L...,
  
• Brady Davis,
  President